Immunogenicity and safety of a second dose of measles-mumps-rubella- varicella vaccine in healthy children aged 5 to 6 years

Pediatric Infectious Disease Journal

Volumn 26, Issue 2, 2007, Pages 153-158

  Vesikari, Timo ^a   Baer, Maija ^a   Willems, Paul ^b  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

immunogenicity; Measles mumps rubella varicella vaccine; safety; varicella

Indexed keywords

MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; RUBELLA ANTIBODY; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEBRILE CONVULSION; FEMALE; HUMAN; IMMUNOGENICITY; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MENINGITIS; NAUSEA; NORMAL HUMAN; OTITIS MEDIA; PAROTID GLAND SWELLING; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SALIVARY GLAND SWELLING; SINGLE DRUG DOSE; SYMPTOM; VACCINATION;

ANTIBODIES, VIRAL; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; EDEMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FEVER; FINLAND; HERPESVIRUS 3, HUMAN; HUMANS; MALE; MEASLES VIRUS; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS VIRUS; PAIN; RUBELLA VIRUS; VACCINES, COMBINED;

EID: 33846576552     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000250689.09396.21     Document Type: Article

References (25)

1. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1998;47:1-57.
2. Wellington K, Goa KL. Measles, mumps, rubella vaccine (Priorix™; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Drugs. 2003;63:2107-2126.
3. Peltola H, Heinonen O, Valle M, et al. Elimination of indigenous measles, mumps and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med. 1994;331:1397-1402.
4. Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med. 1984;310:1409-1415.
5. Varis T, Vesikari T. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis. 1996;174(suppl 3):S330-334.
6. Vazquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA. 2004;291:851-854.
7. Watson B, Boardman C, Laufer D, et al. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis. 1995;20:316-319.
8. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23:132-137.
9. Advisory Committee on Immunization Practices (ACIP). Provisional recommendations for the prevention of varicella. Available at: www.cdc.gov/nip/vaccine/varicella/varicella_acip_recs_prov_june_2006.pdf. Accessed September 2006.
10. Stuck B, Stehr K, Bock HL. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pac J Allergy Immunol. 2002;20:113-120.
11. Brunell PA, Novelli VM, Lipton SV, Pollock B. Combined vaccine against measles, mumps, rubella, and varicella. Pediatrics. 1988;81:779-784.
12. Vesikari T, Ohrling A, Baer M, Delem A, Bogaerts H, Andre FE. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17 month-old children. Acta Paediatr Scand. 1991;80:1051-1057.
13. Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children. J Infect Dis. 1996;173:731-734.
14. White CJ, Stinson D, Staehle B, et al. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group. Clin Infect Dis. 1997;24:925-931.
15. Nolan T, McIntyre P, Roberton D, Descamps D. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine. 2002;21:281-289.
16. Vesikari T, Baer M, Vandevoorde D. An early dose-finding study for an experimental MMRV vaccine [Abstract]. In: 4th World Congress of The World Society of Paediatric Infectious Diseases; Warsaw, Poland; September 1-4, 2005.
17. Miller E, Hill A, Morgan-Capner P, Forsey T, Rush M. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine. 1995;13:799-802.
18. Usonis V, Bakasenas V, Denis M. Neutralization activity and persistence of antibodies induced in response to vaccination with a novel mumps strain, RIT 4385. Infection. 2001;29:159-162.
19. Kreth HW, Hoeger PH. Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis. Eur J Pediatr. 2006;165:677-683.
20. Dubey AP, Banerjee S. Measles, mumps, rubella (MMR) vaccine. Indian J Pediatr. 2003;70:579-584.
21. Knuf M, Habermehl P, Zepp F, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J. 2006;25:12-18.
22. Reisinger KS, Hoffman Brown ML, Xu J, et al. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Pediatrics. 2006;117:265-272.
23. Vesikari T, André FE, Simoen E, et al. Comparison of the Urabe Am 9-Schwarz and Jeryl Lynn-Moraten combinations of mumps-measles vaccines in young children. Acta Paediatr Scand. 1983;72:41-46.
24. Lieberman JM, Williams WR, Miller JM, et al. The safety and Immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: A study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J. 2006;25:615-622.
25. Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24:665-669.